A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

Opioid Dependence Clinical Trial

— PRO-810  

Official title:

A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00768482
• Other study ID #: PRO-810
• Status: Terminated
• Phase: Phase 3
• Start date: September 2008
• Est. completion date: December 2008

Study information

• Verified date: June 2017
• Source: Titan Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).

Description:

This is an open-label study intended to evaluate the relative bioavailability of 4 Probuphine implants versus 16mg QD sublingual buprenorphine, as determined by plasma BPN AUC(0-24), during 24 hours at steady state. This study will also provide open-label safety and tolerability data in patients treated with Probuphine.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Voluntarily provide written informed consent prior to the conduct of any study related procedures

• Male or female, 18-75 years of age

• Meet the DSM-IV criteria for current opioid dependence

• Females of childbearing potential and fertile males must use a reliable means of contraception

Exclusion Criteria:

• Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS)

• Received treatment for opioid dependence (e.g., methadone, BPN) within the previous 90 days

• Current diagnosis of chronic pain requiring opioids for treatment

• Candidates for only short term opioid treatment or opioid detoxification therapy

• Pregnant or lactating females

• Previous hypersensitivity or allergy to BPN or EVA-containing substances or naloxone

• Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)

• Current history of coagulopathy, and/or anti-coagulant therapy (such as warfarin)

• Meet the DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives)

• Current use of benzodiazepines other than physician prescribed use

• Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent

• Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study

• Participated in a clinical study within the previous 8 weeks

• Previous participation in a Probuphine clinical trial

• Presence of aspartate aminotransferase (AST) levels greater than or equal to 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels greater than or equal to 3 X upper limit of normal and/or total bilirubin greater than or equal to 1.5 X upper limit of normal and/or creatinine greater than or equal to 1.5 X upper limit of normal

• Clinically significant low platelet count with current history of coagulopathy

Related Conditions & MeSH terms

• Opioid Dependence
• Opioid-Related Disorders

Intervention

Drug:
• Probuphine (buprenorphine implant)
Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
• Sublingual Buprenorphine
16 mg/day, QD

Locations

Country	Name	City	State
United States	Segal Institute For Clinical Research	Fort Lauderdale	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Titan Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma BPN AUC(0-24)during 24 hours at steady state.		Day -1, Day -2 and Week 4
Secondary	Plasma BPN and NorBPN Cmax		week 4
Secondary	Time to maximum plasma BPN and NorBPN concentration (tmax)		Day -2, Day -1 and Day 1
Secondary	Plasma BPN and NorBPN AUC(0-24) during 24 hours at steady state		week 4
Secondary	Change in plasma BPN concentration		24 weeks
Secondary	Number of subjects with adverse events as a measure of safety and tolerability	Adverse events that occurred after the signing of informed consent until 14 days after study drug treatment has been discontinued, or AEs designated as possibly-related to study drug and Serious AEs until resolution or stabilization, were followed.	approx. 11 weeks (due to study termination)

External Links

•   Link